Literature DB >> 23692855

Gain-of-function Lyn induces anemia: appropriate Lyn activity is essential for normal erythropoiesis and Epo receptor signaling.

Neli S Slavova-Azmanova1, Nicole Kucera, Jiulia Satiaputra, Leah Stone, Aaron Magno, Mhairi J Maxwell, Cathy Quilici, Wendy Erber, S Peter Klinken, Margaret L Hibbs, Evan Ingley.   

Abstract

Lyn is involved in erythropoietin (Epo)-receptor signaling and erythroid homeostasis. Downstream pathways influenced following Lyn activation and their significance to erythropoiesis remain unclear. To address this, we assessed a gain-of-function Lyn mutation (Lyn(up/up)) on erythropoiesis and Epo receptor signaling. Adult Lyn(up/up) mice were anemic, with dysmorphic red cells (spherocyte-like, acanthocytes) in their circulation, indicative of hemolytic anemia and resembling the human disorder chorea acanthocytosis. Heterozygous Lyn(+/up) mice became increasingly anemic with age, indicating that the mutation was dominant. In an attempt to overcome this anemia, extramedullary erythropoiesis was activated. As the mice aged, the levels of different immature erythroid populations changed, indicating compensatory mechanisms to produce more erythrocytes were dynamic. Changes in Epo signaling were observed in Lyn(+/up) erythroid cell lines and primary CD71(+) Lyn(up/up) erythroblasts, including significant alterations to the phosphorylation of Lyn, the Epo receptor, Janus kinase 2, Signal Transducer and Action of Transcription-5, GRB2-associated-binding protein-2, Akt, and Forkhead box O3. As a consequence of altered Lyn signaling, Lyn(+/up) cells remained viable in the absence of Epo but displayed delayed Epo-induced differentiation. These data demonstrate that Lyn gene dosage and activity are critical for normal erythropoiesis; constitutively active Lyn alters Epo signaling, which in turn produces erythroid defects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23692855     DOI: 10.1182/blood-2012-10-463158

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.

Authors:  Viktoria Kohlhas; Michael Hallek; Phuong-Hien Nguyen
Journal:  Blood Adv       Date:  2020-12-22

Review 2.  Diagnosis and treatment of chorea syndromes.

Authors:  Andreas Hermann; Ruth H Walker
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

3.  Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis.

Authors:  Ebun Omoyinmi; Ariane Standing; Annette Keylock; Fiona Price-Kuehne; Sonia Melo Gomes; Dorota Rowczenio; Sira Nanthapisal; Thomas Cullup; Rodney Nyanhete; Emma Ashton; Claire Murphy; Megan Clarke; Helena Ahlfors; Lucy Jenkins; Kimberly Gilmour; Despina Eleftheriou; Helen J Lachmann; Philip N Hawkins; Nigel Klein; Paul A Brogan
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

Review 4.  Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders.

Authors:  Elena Tibaldi; Enrica Federti; Alessandro Matte; Iana Iatcenko; Anand B Wilson; Veronica Riccardi; Mario Angelo Pagano; Lucia De Franceschi
Journal:  Antioxidants (Basel)       Date:  2020-04-24

5.  Deciphering the Key Pharmacological Pathways and Targets of Yisui Qinghuang Powder That Acts on Myelodysplastic Syndromes Using a Network Pharmacology-Based Strategy.

Authors:  Zijian Han; Luping Song; Kele Qi; Yang Ding; Mingjun Wei; Yongcun Jia
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-08       Impact factor: 2.629

6.  A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis.

Authors:  Francesca Lupo; Elena Tibaldi; Alessandro Matte; Alok K Sharma; Anna Maria Brunati; Seth L Alper; Carlo Zancanaro; Donatella Benati; Angela Siciliano; Mariarita Bertoldi; Francesca Zonta; Alexander Storch; Ruth H Walker; Adrian Danek; Benedikt Bader; Andreas Hermann; Lucia De Franceschi
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.